Drug Approval | December 28, 2021
Strides to market molnupiravir under the brand name Stripiravir
Molnupiravir is an orally administered form of a potent ribonucleoside analog that inhibits the replication of SARS-CoV-2
Molnupiravir is an orally administered form of a potent ribonucleoside analog that inhibits the replication of SARS-CoV-2
The company will market it under the brand name Molflu
The company has developed the API in house at its R&D center in Hyderabad
Sucharita brings with her a rich and varied experience of two decades in Information Technology and Financial Services
He has over 22 years of experience in pharmaceutical sales & business development
The proposed scheme to include low-income NRIs under Ayushman Bharat (PM-JAY) would ensure life-long coverage for each individual along with their spouses
Vakrangee through its Nextgen Kendras and BharatEasy Mobile Superaap will now be able to provide medicines & healthcare services in remote areas of the country
Dahiwadkar currently heads four technology companies- WipeOut Inc, Cognota Healthcare Technologies, IT Shastra India and Moringa Techsolv, which he has founded
Syngene will also build and operate a new dedicated drug development laboratory to accelerate the advancement of Amgen R&D projects
This round of funding will support Fast&Up and Chicnutrix to expand their domestic presence, enhance manufacturing capabilities and accelerate momentum globally
Subscribe To Our Newsletter & Stay Updated
